nach oben

Erschienen in:

01.06.2013 | Educational Series – Blue Series

Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials

verfasst von: P. Severino, J. F. Fangueiro, S. V. Ferreira, R. Basso, M. V. Chaud, M. H. A. Santana, A. Rosmaninho, E. B. Souto

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Basal cell carcinomas and squamous cell carcinomas are non-melanoma skin cancers reported to be among the most common malignancies, being responsible for high human morbidity. Conventional chemotherapy applied to these conditions shows non-specific targeting, thus severe adverse side effects are also commonly reported. New therapeutic strategies based on nanoparticulates technology have emerged as alternatives for site specific chemotherapy. Among the different types of nanoparticulates, lipid nanoemulsions and nanoparticles have several advantages for topical delivery of poorly soluble chemotherapeutics. These particles show sustained drug release and protection of loaded drugs from chemical degradation. This technology is promising to enhance the intracellular concentration of drugs and consequently reduce the cytotoxicity of skin chemotherapy.

Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W et al (2011) Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 63(6):470–491PubMedCrossRef

Garduno-Ramirez ML, Clares B, Dominguez-Villegas V, Peraire C, Ruiz MA, Garcia ML et al (2012) Skin permeation of cacalol, cacalone and 6-epi-cacalone sesquiterpenes from a nanoemulsion. Nat Prod Commun 7(7):821–823PubMed

Chen Y, Wu Q, Zhang Z, Yuan L, Liu X, Zhou L (2012) Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules 17(5):5972–5987PubMedCrossRef

Chen YC, Liu DZ, Liu JJ, Chang TW, Ho HO, Sheu MT (2012) Development of terbinafine solid lipid nanoparticles as a topical delivery system. Int J Nanomedicine 7:4409–4418PubMed

Desai P, Patlolla RR, Singh M (2011) Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol 27(7):247–259CrossRef

Chen Y, Zhou L, Yuan L, Zhang ZH, Liu X, Wu Q (2012) Formulation, characterization, and evaluation of in vitro skin permeation and in vivo pharmacodynamics of surface-charged tripterine-loaded nanostructured lipid carriers. Int J Nanomed 7:3023–3033

Gupta M, Vyas SP (2012) Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids 165(4):454–461

Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, Blanco-Prieto MJ (2009) Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol 5(4):323–343PubMedCrossRef

Pawar KR, Babu RJ (2010) Polymeric and lipid-based materials for topical nanoparticle delivery systems. Crit Rev Ther Drug Carrier Syst 27(5):419–459PubMedCrossRef

10.

de Leeuw J, de Vijlder HC, Bjerring P, Neumann HA (2009) Liposomes in dermatology today. J Eur Acad Dermatol Venereol 23(5):505–516PubMedCrossRef

11.

Pardeike J, Hommoss A, Muller RH (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366(1–2):170–184PubMedCrossRef

12.

Souto EB, Muller RH (2008) Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci 30(3):157–165PubMedCrossRef

13.

Roy SD, Gutierrez M, Flynn GL, Cleary GW (1996) Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. J Pharm Sci 85(5):491–495PubMedCrossRef

14.

Lee SH, Jeong SK, Ahn SK (2006) An update of the defensive barrier function of skin. Yonsei Med J 47(3):293–306PubMedCrossRef

15.

Schittek B (2011) The antimicrobial skin barrier in patients with atopic dermatitis. Curr Probl Dermatol 41:54–67PubMedCrossRef

16.

Baroli B (2009) Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci 99(1):21–50CrossRef

17.

Passeron T, Ortonne JP (2003) Skin ageing and its prevention. Presse Med 32(31):1474–1482PubMed

18.

Kristl J, Teskac K, Grabnar PA (2010) Current view on nanosized solid lipid carriers for drug delivery to the skin. J Biomed Nanotechnol 6(5):529–542PubMedCrossRef

19.

Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M (2003) Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 42(1):1–36PubMedCrossRef

20.

Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP et al (2012) Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol (in press)

21.

Grant WB (2012) On the roles of solar UV irradiance and smoking on the diagnosis of second cancers after diagnosis of melanoma. Dermatoendocrinol 4(1):12–17PubMedCrossRef

22.

Pfeifer GP, Besaratinia A (2011) UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer. Photochem Photobiol Sci 11(1):90–97PubMedCrossRef

23.

Andrade P, Brites MM, Vieira R, Mariano A, Reis JP, Tellechea O et al (2012) Epidemiology of basal cell carcinomas and squamous cell carcinomas in a Department of Dermatology: a 5 year review. An Bras Dermatol 87(2):212–219PubMedCrossRef

24.

Clarke P (2012) Nonmelanoma skin cancers—treatment options. Aust Fam Physician 41(7):476–480PubMed

25.

Samarasinghe V, Madan V (2012) Nonmelanoma skin cancer. J Cutan Aesthet Surg 5(1):3–10PubMedCrossRef

26.

Grachtchouk M, Pero J, Yang SH, Ermilov AN, Michael LE, Wang A et al (2011) Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J Clin Invest 121(5):1768–1781PubMedCrossRef

27.

Chinem VP, Miot HA (2011) Epidemiology of basal cell carcinoma. An Bras Dermatol 86(2):292–305PubMedCrossRef

28.

Florence ME, Massuda JY, Brocker EB, Metze K, Cintra ML, Souza EM (2011) Angiogenesis in the progression of cutaneous squamous cell carcinoma: an immunohistochemical study of endothelial markers. Clinics (Sao Paulo) 66(3):465–468CrossRef

29.

Samarasinghe V, Madan V, Lear JT (2011) Management of high-risk squamous cell carcinoma of the skin. Expert Rev Anticancer Ther 11(5):763–769PubMedCrossRef

30.

Maddodi N, Setaluri V (2008) Role of UV in cutaneous melanoma. Photochem Photobiol 84(2):528–536PubMedCrossRef

31.

Kruger K, Blume-Peytavi U, Orfanos CE (1999) Basal cell carcinoma possibly originates from the outer root sheath and/or the bulge region of the vellus hair follicle. Arch Dermatol Res 291(5):253–259PubMedCrossRef

32.

Patel RV, Frankel A, Goldenberg G (2011) An update on nonmelanoma skin cancer. J Clin Aesthet Dermatol 4(2):20–27PubMed

33.

Alimoglu Y, Kilic E, Mercan H, Inci E (2011) Metastatic basal cell carcinoma. J Craniofac Surg 22(3):1134–1136PubMedCrossRef

34.

Panelos J, Tarantini F, Paglierani M, Di Serio C, Maio V, Pellerito S et al (2008) Photoexposition discriminates Notch 1 expression in human cutaneous squamous cell carcinoma. Mod Pathol 21(3):316–325PubMedCrossRef

35.

Bolshakov S, Walker CM, Strom SS, Selvan MS, Clayman GL, El-Naggar A et al (2003) p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res 9(1):228–234PubMed

36.

Renzi C, Mastroeni S, Mannooranparampil TJ, Passarelli F, Caggiati A, Potenza C et al (2010) Delay in diagnosis and treatment of squamous cell carcinoma of the skin. Acta Derm Venereol 90(6):595–601PubMedCrossRef

37.

Yanofsky VR, Mercer SE, Phelps RG (2011) Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer 2011:210813PubMed

38.

Sidoroff A, Thaler P (2010) Taking treatment decisions in non-melanoma skin cancer—the place for topical photodynamic therapy (PDT). Photodiagn Photodyn Ther 7(1):24–32CrossRef

39.

Lien MH, Sondak VK (2011) Nonsurgical treatment options for basal cell carcinoma. J Skin Cancer 2011:571734PubMed

40.

O’Bryan KW, Ratner D (2011) The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer. Semin Cutan Med Surg 30(1):57–61PubMedCrossRef

41.

Ackroyd R, Kelty C, Brown N, Reed M (2001) The history of photodetection and photodynamic therapy. Photochem Photobiol 74(5):656–669PubMedCrossRef

42.

Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R et al (2012) Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 132(6):1583–1590PubMedCrossRef

43.

Chen TM, Rosen T, Orengo I (2002) Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature. Dermatol Surg 28(4):344–346PubMedCrossRef

44.

Wu PA, Stern RS (2012) Topical tretinoin, another failure in the pursuit of practical chemoprevention for non-melanoma skin cancer. J Investig Dermatol 132(6):1532–1535PubMedCrossRef

45.

Osiecka B, Jurczyszyn K, Symonowicz K, Bronowicz A, Ostasiewicz P, Czapinska E et al (2010) In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester. Cell Mol Biol Lett 15(4):630–650PubMedCrossRef

46.

Barolet D, Boucher A (2011) No-needle jet intradermal aminolevulinic Acid photodynamic therapy for recurrent nodular Basal cell carcinoma of the nose: a case report. J Skin Cancer 2011:790509PubMed

47.

Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID (2004) Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg 74(8):704–705PubMedCrossRef

48.

Teskac K, Kristl J (2010) The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 390(1):61–69PubMedCrossRef

49.

Shi G, Rao L, Yu H, Xiang H, Yang H, Ji R (2008) Stabilization and encapsulation of photosensitive resveratrol within yeast cell. Int J Pharm 349(1–2):83–93PubMedCrossRef

50.

Rigel DS, Torres AM, Ely H (2008) Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J Drugs Dermatol 7(1 Suppl 1):s15–s16PubMed

51.

Dragicevic-Curic N, Winter S, Krajisnik D, Stupar M, Milic J, Graefe S et al (2010) Stability evaluation of temoporfin-loaded liposomal gels for topical application. J Liposome Res 20(1):38–48PubMedCrossRef

52.

Henkin RI (2012) Vismodegib in advanced basal-cell carcinoma. N Engl J Med 367(10):969–971CrossRef

53.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171–2179PubMedCrossRef

54.

Amini S, Viera MH, Valins W, Berman B (2010) Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol 3(6):20–34

55.

Smith V, Walton S (2011) Treatment of facial basal cell carcinoma: a review. J Skin Cancer 2011:380371PubMed

56.

Lambert T, Mullinax K, Smith J (2006) A case of an adverse reaction to topical 5-fluorouracil in irradiated skin. J Drugs Dermatol 5(3):282–283PubMed

57.

Hosmer JM, Shin SH, Nornoo A, Zheng H, Lopes LB (2010) Influence of internal structure and composition of liquid crystalline phases on topical delivery of paclitaxel. J Pharm Sci (in press)

58.

Paolino D, Celia C, Trapasso E, Cilurzo F, Fresta M (2012) Paclitaxel-loaded ethosomes(R): potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. Eur J Pharm Biopharm 81(1):102–112PubMedCrossRef

59.

Ndiaye M, Philippe C, Mukhtar H, Ahmad N (2011) The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges. Arch Biochem Biophys 508(2):164–170PubMedCrossRef

60.

Roy P, Kalra N, Prasad S, George J, Shukla Y (2009) Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res 26(1):211–217PubMedCrossRef

61.

Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW et al (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297):218–220PubMedCrossRef

62.

Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27(7):571–577PubMedCrossRef

63.

Amaria RN, Bowles DW, Lewis KD, Jimeno A (2012) Vismodegib in basal cell carcinoma. Drugs Today (Barc) 48(7):459–467

64.

Dirix L, Rutten A (2012) Vismodegib: a promising drug in the treatment of basal cell carcinomas. Future Oncol 8(8):915–928PubMedCrossRef

65.

Paszko E, Ehrhardt C, Senge MO, Kelleher DP, Reynolds JV (2011) Nanodrug applications in photodynamic therapy. Photodiagn Photodyn Ther 8(1):14–29CrossRef

66.

Durbec M, Cosmidis A, Fuchsmann C, Ramade A, Ceruse P (2012) Efficacy and safety of photodynamic therapy with temoporfin in curative treatment of recurrent carcinoma of the oral cavity and oropharynx. Eur Arch Otorhinolaryngol (in press)

67.

Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi-Heyob M (2008) Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 26(11):612–621PubMedCrossRef

68.

Krishnan G, Roberts MS, Grice J, Anissimov YG, Benson HA (2010) Enhanced transdermal delivery of 5-aminolevulinic acid and a dipeptide by iontophoresis. Biopolymers 96(2):166–171CrossRef

69.

Lee Y, Baron ED (2011) Photodynamic therapy: current evidence and applications in dermatology. Semin Cutan Med Surg 30(4):199–209PubMedCrossRef

70.

Tran MA, Watts RJ, Robertson GP (2009) Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res 22(4):388–399PubMedCrossRef

71.

Goutayer M, Dufort S, Josserand V, Royere A, Heinrich E, Vinet F et al (2010) Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm 75(2):137–147PubMedCrossRef

72.

Morgillo F, Lee HY (2005) Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 8(5):298–310PubMedCrossRef

73.

Cho KJ, Wang X, Nie S, Chen ZG, Shin DM (2008) Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310–1316PubMedCrossRef

74.

Kairemo K, Erba P, BergströK J, Pauwels EKJ (2008) Nanoparticles in cancer. Curr Radiopharm 1:30–36CrossRef

75.

Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760

76.

Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA (2007) Variables influencing interactions of untargeted quantum dot nanoparticles with skin cells and identification of biochemical modulators. Nano Lett 7(5):1344–1348PubMedCrossRef

77.

Verma DD, Verma S, Blume G, Fahr A (2003) Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 258(1–2):141–151PubMedCrossRef

78.

Marie-Alexandrine B, Stephanie B, Yves C (2011) Nanoparticles through the skin: managing conflicting results of inorganic and organic particles in cosmetics and pharmaceutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol (in press)

79.

Hia J, Nasir A (2011) Photonanodermatology: the interface of photobiology, dermatology and nanotechnology. Photodermatol Photoimmunol Photomed 27(1):2–9PubMedCrossRef

80.

Kogan A, Garti N (2006) Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 123–126:369–385PubMedCrossRef

81.

Spernath A, Aserin A (2006) Microemulsions as carriers for drugs and nutraceuticals. Adv Colloid Interface Sci 128–130:47–64PubMedCrossRef

82.

Anton N, Vandamme TF (2010) Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm Res 28(5):978–985PubMedCrossRef

83.

Araujo FA, Kelmann RG, Araujo BV, Finatto RB, Teixeira HF, Koester LS (2010) Development and characterization of parenteral nanoemulsions containing thalidomide. Eur J Pharm Sci 42(3):238–245PubMedCrossRef

84.

Tagne JB, Kakumanu S, Nicolosi RJ (2008) Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model. Mol Pharm 5(6):1055–1063PubMedCrossRef

85.

Shakeel F, Ramadan W (2010) Transdermal delivery of anticancer drug caffeine from water-in-oil nanoemulsions. Colloids Surf B Biointerfaces 75(1):356–362PubMedCrossRef

86.

Araujo LM, Thomazine JA, Lopez RF (2010) Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy. Eur J Pharm Biopharm 75(1):48–55PubMedCrossRef

87.

Lin C–C, Lin H-Y, Chen H-C, Yu M-W, Lee M-H (2009) Stability and characterisation of phospholipid-based curcumin-encapsulated microemulsions. Food Chem 116(4):923–928CrossRef

88.

Liu CH, Chang FY, Hung DK (2011) Terpene microemulsions for transdermal curcumin delivery: effects of terpenes and cosurfactants. Colloids Surf B Biointerfaces 82(1):63–70PubMedCrossRef

89.

Kakumanu S, Tagne JB, Wilson TA, Nicolosi RJ (2011) A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension. Nanomedicine 7(3):277–283PubMedCrossRef

90.

Kristl J, Teskac K, Milek M, Mlinaric-Rascan I (2008) Surface active stabilizer tyloxapol in colloidal dispersions exerts cytostatic effects and apoptotic dismissal of cells. Toxicol Appl Pharmacol 232(2):218–225PubMedCrossRef

91.

Schafer-Korting M, Mehnert W, Korting HC (2007) Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 59(6):427–443PubMedCrossRef

92.

Singhal GB, Patel RP, Prajapati BG, Patel NA (2011) Solid lipid nanoparticles and nano lipid carriers: as novel solid lipid based drug carrier. Int Res J Pharm 2(2):20–52

93.

Mudshinge SR, Deore AB, Patil S, Bhalgat CM (2011) Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J 19(3):129–141CrossRef

94.

Nikolic S, Keck CM, Anselmi C, Müller RH (2011) Skin photoprotection improvement: synergistic interaction between lipid nanoparticles and organic UV filters. Int J Pharm 414(1–2):276–284PubMedCrossRef

95.

Mandawgade SD, Patravale VB (2008) Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm 363(1–2):132–138PubMedCrossRef

96.

Shah KA, Date AA, Joshi MD, Patravale VB (2007) Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm 345(1–2):163–171PubMedCrossRef

97.

Abdel-Mottaleb MMA, Neumann D, Lamprecht A (2011) Lipid nanocapsules for dermal application: a comparative study of lipid-based versus polymer-based nanocarriers. Eur J Pharm Biopharm (In Press, Corrected Proof)

98.

David S, Carmoy N, Resnier P, Denis C, Misery L, Pitard B et al (2011) In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model. Int J Pharm 423(1):108–115PubMedCrossRef

99.

Weiss MB, Aplin AE (2010) Paying “particle” attention to novel melanoma treatment strategies. J Invest Dermatol 130(12):2699–2701PubMedCrossRef

100.

Huynh NT, Passirani C, Saulnier P, Benoit JP (2009) Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 379(2):201–209PubMedCrossRef

101.

Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP (2002) A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 19(6):875–880PubMedCrossRef

102.

Ourique AF, Melero A, de Bona da Silva C, Schaefer UF, Pohlmann AR, Guterres SS et al (2011) Improved photostability and reduced skin permeation of tretinoin: development of a semisolid nanomedicine. Eur J Pharm Biopharm 79(1):95–101

Titel: Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials
verfasst von: P. Severino
J. F. Fangueiro
S. V. Ferreira
R. Basso
M. V. Chaud
M. H. A. Santana
A. Rosmaninho
E. B. Souto
Publikationsdatum: 01.06.2013
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 6/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0982-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

A novel peptide (Thx) homing to non-small cell lung cancer identified by ex vivo phage display

Is it necessary to dissect the lymph nodes around an abnormal hepatic artery in D2 lymphadenectomy for gastric cancer?

Comparisons of 5-aminolevulinic acid photodynamic therapy and after-loading radiotherapy in vivo in cervical cancer

Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes

Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey

Erratum to: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie